CannPal Animal Therapeutics Limited

CannPal Animal Therapeutics Limited (CP1) is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The Company is established to research, develop and commercialise regulatory approved, cannabinoid-derived therapeutics, for the global animal health markets, with an initial focus on cats and dogs, in the United States, Europe, Australia and other emerging global markets.